Roche Submits Application To FDA To Market CERA For The Treatment Of Renal Anaemia

... Roche a world leader in biotechnology today announced it has submitted a Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) to market CERA for the treatment of anaemia associated with chronic kidney disease (CKD) including patients on dialysis and not on dialysis. CERA, an innovative investigational anti-anaemia agent, is the first and only continuous erythropoietin receptor activator... click link for more info. ...